Gossamer Bio Regains Full Control of Seralutinib as It Preps for September NDA Submission
Event summary
- Gossamer Bio reacquired worldwide rights to seralutinib from Chiesi for a $5 million one-time payment, terminating their prior collaboration agreement.
- The company plans to submit its New Drug Application (NDA) for seralutinib in pulmonary arterial hypertension (PAH) in September 2026, following a productive Pre-NDA Type B meeting with the FDA.
- Gossamer exchanged approximately $181.1 million of its convertible notes, reducing debt by about $115.9 million and extending maturity to 2030.
- Q2 2026 revenue was $9.2 million, down from $11.5 million in Q2 2025, while net income improved to $16.9 million from a loss of $38.3 million.
The big picture
Gossamer Bio is consolidating its operational control ahead of a critical regulatory milestone for its lead asset, seralutinib. The company's debt restructuring and regaining full rights to the drug signal a strategic pivot toward self-sufficiency in development and commercialization. This move comes as Gossamer navigates a competitive landscape in pulmonary hypertension treatments, where regulatory approvals can significantly alter market dynamics.
What we're watching
- Regulatory Timing
- Whether the FDA will accept Gossamer's NDA submission for seralutinib in September 2026 and the potential approval decision timeline in Q3 2027.
- Financial Runway
- How long Gossamer's $57 million cash position will last, given its operating plan extending into Q1 2027.
- Commercial Strategy
- The impact of regaining full control over seralutinib's global development and commercialization on Gossamer's long-term market positioning.
Related topics